UBS Group’s Longevity Acquisition Corporation Units LOACU Stock Holding History

UBS Group’s Portfolio LOACU Stock Details LOACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,716	Closed	-$18K	–	8597
2020 Q1	$18K	Hold	1,716	–	–	﹤0.01%	6570
2019 Q4	$18K	Hold	1,716	–	–	﹤0.01%	6960
2019 Q3	$18K	Sell	1,716 -1,303	-43%	-$13.6K	﹤0.01%	6812
2019 Q2	$31K	Sell	3,019 -270	-8%	-$2.8K	﹤0.01%	6320
2019 Q1	$34K	Sell	3,289 -950	-22%	-$9.69K	﹤0.01%	5854
2018 Q4	$43K	Buy	4,239 +3,685	+665%	+$37.6K	﹤0.01%	6237
2018 Q3	$6K	Buy	+554	New	+$5.66K	﹤0.01%	7437

Other funds holding LOACU

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

UBS Group's LOACU Position: Q2 2020 in Review

UBS Group sold out of Longevity Acquisition Corporation Units (LOACU) in Q2 2020, closing a stake of 1,716 shares — an estimated $18K sold.

UBS Group first reported a position in LOACU in Q3 2018 and held it in 7 quarters. The position peaked at $43K in Q4 2018. 1 fund tracked by Wall St. Rank holds LOACU as of Q2 2020.

UBS Group reported no remaining Longevity Acquisition Corporation Units position as of Q2 2020 after selling out during the quarter.
UBS Group sold 1,716 Longevity Acquisition Corporation Units shares in Q2 2020, an estimated $18K.
UBS Group first reported a position in Longevity Acquisition Corporation Units in Q3 2018 and held it in 7 quarters.
UBS Group's Longevity Acquisition Corporation Units position peaked at $43K in Q4 2018.
1 fund tracked by Wall St. Rank held Longevity Acquisition Corporation Units as of Q2 2020.

Based on UBS Group's 13F filing for Q2 2020, filed 31 Jul 2020.